These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37195967)

  • 1. PIK3CA mutations in breast cancer: A Tunisian series.
    Ben Rekaya M; Sassi F; Saied E; Bel Haj Kacem L; Mansouri N; Zarrouk S; Azouz S; Rammeh S
    PLoS One; 2023; 18(5):e0285413. PubMed ID: 37195967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PIK3CA gene mutations in Chinese women with HR
    Wu SF; Wang XF; Liu YY; Xia C; Liang ZY; Zeng X
    Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1246-1250. PubMed ID: 36480834
    [No Abstract]   [Full Text] [Related]  

  • 3. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
    Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
    Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
    Ahmad F; Badwe A; Verma G; Bhatia S; Das BR
    Med Oncol; 2016 Jul; 33(7):74. PubMed ID: 27282497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel PIK3CA hot-spot mutation in breast cancer patients detected by HRM-COLD-PCR analysis.
    Debouki-Joudi S; Ben Kridis W; Trifa F; Ayadi W; Khabir A; Sellami-Boudawara T; Daoud J; Khanfir A; Mokdad-Gargouri R
    Breast Dis; 2024; 43(1):213-221. PubMed ID: 38943378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
    Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
    Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
    Schneck H; Blassl C; Meier-Stiegen F; Neves RP; Janni W; Fehm T; Neubauer H
    Mol Oncol; 2013 Oct; 7(5):976-86. PubMed ID: 23895914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
    Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
    Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
    Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
    Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.
    Gasch C; Oldopp T; Mauermann O; Gorges TM; Andreas A; Coith C; Müller V; Fehm T; Janni W; Pantel K; Riethdorf S
    Mol Oncol; 2016 Oct; 10(8):1330-43. PubMed ID: 27491860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Liquid Biopsy to Detect PIK3CA Mutation in Metastatic Breast Cancer.
    Nakai M; Yamada T; Sekiya K; Sato A; Hankyo M; Kuriyama S; Takahashi G; Kurita T; Yanagihara K; Yoshida H; Ohashi R; Takei H
    J Nippon Med Sch; 2022 Mar; 89(1):66-71. PubMed ID: 33692304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Helical and kinase domain mutations of
    Vatte C; Al Amri AM; Cyrus C; Chathoth S; Alsayyah A; Ahmad A; Akhtar MS; Alrashidi NF; Jayaseeli N; Al Wadani H; Al Zahrani A; Al Ali AK
    Oncol Lett; 2019 Sep; 18(3):2427-2433. PubMed ID: 31404155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA-mutations in breast cancer.
    Reinhardt K; Stückrath K; Hartung C; Kaufhold S; Uleer C; Hanf V; Lantzsch T; Peschel S; John J; Pöhler M; Bauer M; Bürrig FK; Weigert E; Buchmann J; Kantelhardt EJ; Thomssen C; Vetter M
    Breast Cancer Res Treat; 2022 Dec; 196(3):483-493. PubMed ID: 36279023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.
    Cheng J; Fu S; Wei C; Tania M; Khan MA; Imani S; Zhou B; Chen H; Xiao X; Wu J; Fu J
    Cancer Biomark; 2017; 19(1):85-92. PubMed ID: 28269754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
    Guo S; Loibl S; von Minckwitz G; Darb-Esfahani S; Lederer B; Denkert C
    Cancer Res Treat; 2020 Jul; 52(3):689-696. PubMed ID: 32019278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical-Pathologic Analysis of Breast Cancer With PIK3CA Mutations in Chinese Women.
    Lian J; Xu EW; Xi YF; Wang HW; Bu P; Wang JF; Wang LX
    Technol Cancer Res Treat; 2020; 19():1533033820950832. PubMed ID: 33047659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients.
    Filipenko ML; Os'kina NA; Oskorbin IA; Mishukova OV; Ovchinnikova LK; Gershtein ES; Kushlinskii NE
    Bull Exp Biol Med; 2017 Jun; 163(2):250-254. PubMed ID: 28726194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing.
    Jia M; Liao N; Chen B; Zhang G; Wang Y; Li X; Cao L; Mok H; Ren C; Li K; Li C; Wen L; Lin J; Wei G; Balch CM
    Breast Cancer; 2021 May; 28(3):644-652. PubMed ID: 33386585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.
    Deng L; Zhu X; Sun Y; Wang J; Zhong X; Li J; Hu M; Zheng H
    Cancer Res Treat; 2019 Jan; 51(1):128-140. PubMed ID: 29540052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
    Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
    World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.